Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, Tesamorelin is FDA-approved to reduce excess visceral adipose tissue in HIV-associated lipodystrophy and is studied for broader body-composition, NAFLD, and cognitive effects via GH/IGF-1 axis modulation1893.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, Tesamorelin is a full-length 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid modification that binds GHRHR, activating cAMP/PKA signaling to increase endogenous GH and IGF-1, with improved stability versus native GHRH182893102.
FOXO4-DRI
FOXO4
Tesamorelin
GHRH
FOXO4-DRI and Tesamorelin are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: FOXO4-DRI is more often discussed in the realm of Aging and longevity, whereas Tesamorelin is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. Their biological logic is quite different: FOXO4-DRI is a protein interaction inhibitor, whereas Tesamorelin is a receptor agonist. FOXO4-DRI has a more synthetic design origin, while Tesamorelin is closer to synthetic analog background and their development context also differs, with FOXO4-DRI in Preclinical development while Tesamorelin is approved. FOXO4-DRI takes the form of a linear peptide, whereas Tesamorelin is closer to a peptide conjugate, FOXO4-DRI carries retro-inverso isomerization features, while Tesamorelin instead reflects amidation changes; while their sequence patterns also diverge, with FOXO4-DRI showing protein-mimetic sequence features and Tesamorelin showing alpha-helical domain features.
No related articles are linked to these peptides yet.